Non-pyrogenic preparation comprising nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications
A non-pyrogenic preparation containing nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications. The nanoparticles are constituted by a crystallized mineral central part including predominantly an iron oxide, as well as a surrounding coating without material from the magnetotactic bacteria.
1. A preparation comprising at least one synthetic nanoparticle, the at least one synthetic nanoparticle comprising:
a crystallized mineral central part comprising predominantly an iron oxide, the central part having been produced by a living organism, and
a coating comprising materials not produced by said living organism, the coating covering the central part completely or partly,
wherein the coating comprises less than 12% in mass of non-denatured proteins from said living organism relative to the mass of the at least one synthetic nanoparticle, and
wherein the coating does not comprise a lipid bilayer that completely covers the central part and that originates from said living organism.
2. The preparation according to claim 1 , wherein the living organism is a bacterium.
3. The preparation according to claim 2 , wherein the bacterium is a magnetotactic bacterium.
4. The preparation according to claim 1 , wherein the central part comprises maghemite and/or magnetite.
5. The preparation according to claim 1 , wherein the at least one synthetic nanoparticle is non-pyrogenic.
6. The preparation according to claim 1 , wherein the at least one synthetic nanoparticle further comprises proteins, and the proteins that are not in the coating are non-denatured proteins.
7. The preparation according to claim 1 , wherein the coating comprises 0% in mass of non-denatured proteins from said living organism relative to the mass of the at least one synthetic nanoparticle.
8. The preparation according to claim 1 , wherein the at least one synthetic nanoparticle comprises no endotoxins.
9. The preparation according to claim 1 , wherein the at least one synthetic nanoparticle comprises an endotoxin quantity, which abides by at least one quality or regulatory standard in force applicable to medical devices, drugs or cosmetic products, in particular conforming to an ISO quality standard or a current pharmacopoeia.
10. The preparation according to claim 1 , wherein the coating of the at least one synthetic nanoparticle enables an arrangement in a chain of at least two synthetic nanoparticles, said at least two synthetic nanoparticles having crystallographic axes orientated in the direction of elongation of the chain.
11. The preparation according to claim 1 , wherein the coating comprises at least one compound able to establish weak interactions or covalent bonds with the central part of the at least one synthetic nanoparticle.
12. The preparation according to claim 1 , wherein the coating comprises at least one compound able to establish interactions or bonds with Fe 2+ or Fe 3+ ions, hydroxyls OH − , oxides 0 2− , or crystalline defects of the central part.
13. The preparation according to claim 1 , wherein the central part has a size comprised between 1 nm and 2 μm.
14. The preparation according to claim 1 , wherein the coating has a thickness larger than 0.1 nm.
15. The preparation according to claim 1 , wherein the coating comprises at least one compound selected from the group consisting of a chelator, an amphipathic molecule, a polarized or charged polymer, a metal or silicon oxide, a hydroxide of a metal or silicon, an acid, an acidic, basic, oxidized, reduced, neutral, positively charged, negatively charged derivative of these compounds, and a combination of several of these compounds or derivatives.
16. The preparation according to claim 1 , wherein the coating comprises at least one compound selected from the group consisting of a polysaccharide, a fatty acid, a phospholipid, a polymer of amino acids, polymeric or non-polymeric silica, and an aliphatic amino polymer, of an acidic, basic, oxidized, reduced, neutral, positively charged, negatively charged derivatives of these compounds and a combination of several of these compounds or derivatives.
17. The preparation according to claim 1 , wherein the coating comprises at least one function selected from the group consisting of carboxylic acids, phosphoric acids, sulfonic acids, esters, amides, ketones, alcohols, phenols, thiols, amines, ether, sulfides, acid anhydrides, acyl halides, amidines, nitriles, hydroperoxides, imines, aldehydes, peroxides, of an acidic, basic, oxidized, reduced, neutral, positively charged, negatively charged derivative of these compounds, and a combination of several of these compounds or derivatives.
18. The preparation according to claim 1 , wherein the coating comprises carbonaceous compounds.
19. The preparation according to claim 18 , wherein the at least one synthetic nanoparticle is prepared by a process comprising the steps of:
obtaining or starting from at least one natural nanoparticle produced by a living organism, the at least one natural nanoparticle comprising a crystallized mineral central part that comprises predominantly an iron oxide and an original surrounding coating that covers the central part;
removing from the central part at least a portion of the original surrounding coating; and
applying a new coating not produced by the living organism to the central part from which the at least a portion of the original surrounding coating has been removed, the new coating covering the central part completely or partly, to form the at least one synthetic nanoparticle, which comprises a coating that comprises less than 12% in mass of non-denatured proteins originating from the living organism that produced the central part relative to the mass of the at least one synthetic nanoparticle, and
wherein the coating does not comprise a lipid bilayer that completely covers the central part and that originates from said living organism.
20. A method for treating a tumor in an individual or animal, wherein a therapeutically active quantity of the preparation according to claim 1 is administered to the individual or animal.
21. A pharmaceutical composition or drug comprising, as active principle, a preparation as defined in claim 1 , and optionally at least one pharmaceutically acceptable carrier.
22. A medical device comprising a preparation as defined in claim 1 .
23. A diagnostic composition comprising a preparation as defined in claim 1 .
24. A cosmetic composition comprising, as cosmetic active principle, a preparation as defined in claim 1 .
25. A method for the manufacture of a preparation as defined in claim 1 , comprising the following steps:
(i) from a preparation of nanoparticles synthesized by a living organism comprising a crystallized central part composed predominantly of an iron oxide and a biological surrounding coating, isolating the central part;
(ii) treating the resulting isolated central part to cover the central part with a coating;
(iii) optionally sterilize the preparation, after step (i) or after step (ii).